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Background: Severe mitral regurgitation (MR) may cause myolysis in the left atrial myocytes. Myolysis may contribute
to atrial enlargement. However, the relationship between Rho-associated kinase (ROCK) and myolysis in the left atrial
myocytes of MR patients remain unclear.
Methods: This study comprised 22 patients with severe MR [12 with atrial fibrillation (AF) and ten in sinus rhythm]. Left
atrial appendage tissues were obtained during surgery. Normal left atrial tissues were purchased. Immunofluorescence
histochemical and immunoblotting studies were performed.
Results: The expression of ROCK2 in the myolytic left atrial myocytes of MR AF patients (p = 0.009) and MR sinus
patients (p = 0.011) were significantly higher than that of the normal subjects. Similarly, the expression of ROCK1 in the
myolytic left atrial myocytes of MR AF patients was significantly higher than that of the normal subjects (p = 0.010), and
the expression of ROCK1 in the myolytic left atrial myocytes of MR sinus patients was higher than that of the normal
subjects (p = 0.091). Immunofluorescence study revealed significant co-localization and juxtaposition of ROCK2 and
cleaved caspase-3 in the left atrial myocytes both in the MR AF group (Pearson’s coefficient = 0.74 ± 0.03) and the
MR sinus group (Pearson’s coefficient = 0.73 ± 0.02). Similarly, immunofluorescence study revealed significant co-localization
and juxtaposition of ROCK1 and cleaved caspase-3 in the left atrial myocytes both in the MR AF group (Pearson’s
coefficient = 0.65 ± 0.03) and the MR sinus group (Pearson’s coefficient = 0.65 ± 0.03). Correlation analysis demonstrated
that there was a significant direct relationship between the expression of ROCK2 in the myolytic left atrial myocytes and
left atrial diameter in the MR patients (p = 0.041; r = 0.440). Moreover, the ratio of phosphorylated myosin-binding subunit
of myosin light chain phosphatase (pMBS)/total MBS of left atrial tissues was significantly higher in the MR AF group
(p < 0.04) and the MR sinus group (p < 0.04) compared with the normal control group.
Conclusions: The enhanced expression of ROCKs might be involved in the myolysis of the left atrial myocytes of
MR patients.
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Valvular heart disease, particularly mitral regurgitation
(MR), is one of the major risk factors of heart failure [1]
and severe MR portends a poor outcome. Significant left
atrial enlargement associated with MR has been known to
correlate with a poor prognosis in patients undergoing mi-
tral valve repair or replacement and is often associated
with the development of atrial fibrillation (AF) [2]. Atrial
fibrillation is the most common cardiac arrhythmia. Previ-
ous Western community-based cohort studies revealed
that AF increased a two-fold risk in mortality [3, 4]. Fur-
thermore, valvular heart disease with heart failure and AF
was linked to increased mortality [5, 6].
Atrial myocardial stretch caused by volume and pres-
sure overload due to significant MR may cause apoptosis.
A previous study revealed that apoptosis occurs in the
atrial myocytes of patients with mitral valve diseases [7].
Apoptosis plays a critical role in myocyte loss [8]. Indeed,
previous studies revealed that myolysis occurs in the atrial
myocytes of patients with mitral valve disease [7, 9–11].
Myolysis may contribute to atrial contractile dysfunction
and consequently, atrial enlargement as well, which has
been reported to be a prognostic factor in patients with
MR [2]. However, the underlying mechanisms of myolysis
remain unclear.
Growing evidence indicates that Rho-associated kinase
(ROCK) activity in human is enhanced in various dis-
eases, including essential hypertension, coronary and
cerebral vasospasm, ischemic heart disease, pulmonary
hypertension, and heart failure [12–17]. ROCKs may
play a role either as a proapoptotic or anti-apoptotic
regulator [18, 19]. The ROCKs mediated apoptosis could
be either caspase 3-dependent or caspase 3-independent
cleavage of ROCKs [19]. However, exactly how ROCK
regulates an apoptotic response is not completely under-
stood in many instances, and is likely different depending
on the cell type and the apoptotic stimulus [20]. There are
two isoforms of ROCKs, ROCK1 and ROCK2 [21, 22].
ROCK2 is distributed mostly in the heart and brain. How-
ever, ROCK1 is mainly expressed in the lung, liver, spleen,
kidney and testis. Similarly, caspase-3, a key mediator of
apoptosis, has a significant role in myocyte apoptosis and
is a therapeutic target in heart failure [23–26]. However,
the relationship between ROCKs and caspase-3 in the
atrial myocytes of heart failure patients due to severe MR
remains unknown. Additionally, the relationship between
ROCKs and myolysis in the left atrial myocytes of MR pa-
tients remain unclear. We hypothesized that there was a
positive correlation between myolysis and the expression
levels of ROCKs in the left atrial myocytes of heart failure
patients due to severe MR. Accordingly, the present study
investigated the expression levels of ROCKs and caspase-3
in the left atrial myocytes of heart failure patients due to
severe MR.Methods
Patient population
This study examined 22 patients with severe symptom-
atic MR who had undergone valve operations for heart
failure. Exclusion criteria were previous myocardial infarc-
tion, febrile disorder, infectious or inflammatory disease,
autoimmune disease, malignancy, chronic renal failure
(serum creatinine >2.5 mg/dL), acute or chronic viral
hepatitis or use of immunosuppressive drugs. Twelve pa-
tients had persistent AF [mean (± SD) duration, 47.8 ±
70.2 months; duration range, 1 to 240 months] before sur-
gery (MR AF patients). The sample included ten males
and two females with a mean (± SD) age of 67 ± 7 years
old (age range, 58 to 81 years old). Ten patients with no
history and no records of electrocardiograms of AF before
surgery had symptomatic severe MR (MR sinus patients).
The sample included two males and eight females with a
mean (± SD) age of 56 ± 10 years old (age range, 33 to
68 years old). Informed consent was obtained from all
study subjects. The study protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki and was ap-
proved by the Institutional Review Committee for Human
Research at our institution. Normal adult left atrial tissue
samples were purchased from BioChain Institute, Inc,
USA, Novus, USA, and G-bioscience, USA for histochem-
ical and immunochemical studies. These normal atrial tis-
sues were used as the normal controls.
Echocardiography
Transthoracic echocardiographic examinations were per-
formed on all patients using a 2.5 MHz transducer at-
tached to a commercially available echo Doppler machine
(Sonos 7500; Hewlett-Packard; Palo Alto, CA) on the day
before valve surgery. Echocardiographic measurements
were performed according to the recommendations of the
American Society of Echocardiography.
Hemodynamic measurements
Measurements of left atrial pressure were performed
within one month before surgery.
Specimen storage
Atrial tissue was sampled from the left atrial appendage.
After excision, atrial tissues were immediately frozen in li-
quid nitrogen or embedded in optimal cutting temperature
compound, and stored at −80 Celsius to be held for later
immunofluorescence staining and immunoblotting.
Immunofluorescence staining
Frozen tissue sections (5 μm) were fixed for 10 min with
4 % paraformaldehyde and then exposed for 50 min in 5 %
BSA (bovine serum albumin), followed by incubation with
the corresponding antibodies in the double staining proce-
dures. Primary antibodies included antibodies against
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phalloidin-FITC F-actin (counterstaining for myocyte
identification; 1:1000 dilution; Sigma, MO, USA), and
cleaved caspase-3 (1:200 dilution; Cell signaling, MA,
USA) at 4 °C overnight. For confocal microscope, the sec-
ondary detection systems were Alex Fluor 488 (green)/594
(red) goat-anti-mouse IgG (AnaSpec, CA, USA) conju-
gated with ROCK2, and Alex Fluor 594 (red) goat-anti-
rabbit IgG (AnaSpec, CA, USA) conjugated with F-actin
and caspase-3 that were diluted 1:500 for 30 min at 37 °C.
Nuclei were stained with Hoechst 33258 (1:1000 dilution;
Sigma, MO, USA). All images of each specimen were cap-
tured and examined at high magnification (600×) using an
Olympus FV10I-Oil confocal microscope (Tokyo, Japan).
For immunostaining quantification, atrial samples
were analyzed with at least 50 randomly chosen cells per
each sample. Cell area, myolytic area, integrated inten-
sities of each antibody (calculated after correction of
background noise), percentage of co-localization, and
Pearson’s coefficient in each myocyte were obtained and
calculated by Olympus Fluoview software (Tokyo,
Japan). The expression levels of ROCK2, ROCK1 and
cleaved caspase 3 were presented as integrated inten-
sities. Atrial myocytes were scored by morphometry as
mildly myolytic if <10 % of the sarcomere content was
absent, and moderately-to severely myolytic if >10 % of
the sarcomere was absent. For co-localization analysis,
the average intensity of each antibody was used as co-
localization threshold.
Three normal adult left atrial tissue samples were pur-
chased from BioChain Institute, Inc, USA (76 female, 70
female, and 24 male).
Western blotting
Tissues extracts were prepared by PRO-PREP™ protein
extraction solution (Intron biotechnology, Gyeonggi-do,
Korea). Homogenates were centrifuged at 14000 rpm for
30 min at 4 °C to yield supernatants. The concentrations
of sample proteins and 3 normal human left atrial proteins
[purchased from Novus, USA (77 male), Biochain, USA
(62 female), and G-bioscience, USA (24 male)] were deter-
mined by the Bradford method (Bio-Rad) according to the
supplier’s instructions. Protein extracts were size-
fractionated using SDS-PAGE electrophoresis at 7 °C
overnight and electro-transferred onto PVDF mem-
branes for 3 h on ice. Membranes were blocked in Tris-
buffered saline, with 0.1 % Tween-20 (TBST) and 5 %
BSA at room temperature for 2 h. Primary antibodies
included phosphorylation level of myosin-binding sub-
unit of myosin light chain phosphatase (pMBS) (1:1000
dilution; Cyclex, Nagano, Japan), total MBS (tMBS)
(1:1000 dilution; Cell signaling, MA, USA), ROCK1
(1:500 dilution; Santa Cruz, CA, USA), ROCK2 (1:500
dilution; Santa Cruz, CA, USA), cleaved caspase-3(1:1000 dilution; Cell signaling, MA, USA) and GAPDH
(1:5000 dilution; Millipore, MA, USA) and were used to
react with the blots at 4 °C overnight in 5 % BSA. The
blots were washed three times in TBST and incubated at
room temperature for 1 h with horseradish peroxidase-
labeled secondary antibody at dilutions of 1:5000 in TBST
containing 5 % BSA. Following three washings, blots were
incubated with Immobilon Western chemiluminescent
HRP substrate (Millipore, MA, USA). Densitometry ana-
lysis was conducted using Quantity One 1-D Analysis
Software (Bio-red, Berkeley, California).
Statistical analysis
Data were presented as means ± SD or SEM. Categorical
variables between the MR AF patients, MR sinus pa-
tients, and the normal control subjects were compared
using chi-square test or Fisher exact test as appropriate.
Moreover, continuous variables in the three groups were
compared using a Kruskal-Wallis test. Continuous vari-
ables between the two groups of study patients were
compared with a Mann–Whitney U test. Co-localization
analysis between the expression site of ROCKs and the
expression site of cleaved caspase-3 in the left atrial
myocytes was performed and presented as Pearson’s cor-
relation coefficient. The correlation between the expres-
sion levels of ROCKs in the left atrial myocytes and left
atrial dimension was performed with the Spearman’s
correlation. Finally, statistical analyses were performed
using the statistical software program (SPSS version
19.0; SPSS Inc.; Chicago, Illinois, U.S.A.). All p values
were two-sided, and the level of statistical significance
was set at 0.05.
Results
Baseline characteristics of patients studied
In this study, all patients were non-smoker, and none
had the history of stroke or thromboembolic events.
Warfarin was administered to all MR patients with AF.
The MR AF patients were older, and included more male
patients than MR sinus patients (Table 1). The MR AF pa-
tients had a poorer renal function (1.21 ± 0.43 mg/dl vs.
0.72 ± 0.18 mg/dl, p < 0.001), and a lower prevalence of dys-
lipidemia (8.3 % vs. 50.0 %, p = 0.043) than the MR sinus
patients. The two groups did not differ significantly in term
of white blood cell count, body mass index, prevalence of
hypertension or diabetes mellitus, and incidence of aortic
or tricuspid valve disease. In this study, there was no differ-
ence in the severity of heart failure, and advanced heart fail-
ure (New York Heart Association functional class ≥3) was
diagnosed in 83.3 % of the MR AF patients, and in 90.0 %
of the MR sinus patients.
The preoperative left atrial size, and left ventricular end-
diastolic and end-systolic sizes were significantly larger in
the MR AF group than the MR sinus group (Table 1). The
Table 1 Baseline clinical characteristics of the study patients
MR sinus (n = 10) MR AF (n = 12) p value
Age (years) 56 ± 10 67 ± 7 0.007
Male (%) 2 (20.0 %) 10 (83.3 %) 0.008
Creatinine (mg/dl) 0.7 ± 0.2 1.2 ± 0.4 <0.001
White blood cell count (103/uL) 6.5 ± 1.9 5.2 ± 1.3 0.069
Body mass index (kg/m2) 24.4 ± 2.1 23.9 ± 3.1 0.628
Hypertension (%) 3 (30.0 %) 6 (50.0 %) 0.415
Diabetes mellitus (%) 2 (20.0 %) 3 (25.0 %) 1.000
Dyslipidemia (%) 5 (50.0 %) 1 (8.3 %) 0.043
Heart failure NYHA classification 2.9 ± 0.3 2.9 ± 0.5 0.961
Functional class II (%) 1 (10.0 %) 2 (16.7 %)
Functional class III (%) 9 (90.0 %) 9 (75.0 %)
Functional class IV (%) 0 (0.0 %) 1 (8.3 %)
Advanced heart failure (%) 9 (90.0 %) 10 (83.3 %) 0.571
Aortic valve disease (%) 0 (0.0 %) 2 (16.7 %) 0.481
Tricuspid valve disease (%) 2 (20 %) 7 (58.3 %) 0.099
Left atrial pressure (mmHg) 17.0 ± 8.4 19.3 ± 7.9 0.424
Left atrial diameter (mm) 41.9 ± 5.7 51.7 ± 8.6 0.007
Left atrial ejection fraction (%) 51.6 ± 17.7 38.2 ± 13.6 0.041
Left ventricular end-diastolic diameter (mm) 54.6 ± 5.3 62.4 ± 8.6 0.029
Left ventricular end-systolic diameter (mm) 34.3 ± 5.9 42.5 ± 7.7 0.019
Left ventricular ejection fraction (%) 66.1 ± 7.9 58.5 ± 10.4 0.086
Beta-blockers (%) 1 (10.0 %) 4 (33.3 %) 0.323
Calcium channel blockers (%) 1 (10.0 %) 4 (33.3 %) 0.323
Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (%) 10 (100.0 %) 10 (83.3 %) 0.481
Statins (%) 1 (10.0 %) 0 (0.0 %) 0.455
Data are presented as mean ± SD or number (percentage).
NYHA, New York Heart Association.
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MR AF group than the MR sinus group (p = 0.043). There
was no difference in left atrial pressure and left ventricular
ejection fraction between the two groups. Furthermore,
the two groups were balanced in terms of use of drugs
such as β-blockers, Ca-channel blockers, angiotensin con-
verting enzyme inhibitors or type I angiotensin II receptor
blockers, and statins.
Myolysis and hypertrophy of cardiomyocytes in mitral
regurgitation
The average cell surface area of myocytes in the left
atrial tissue of the MR AF patients (681.6 ± 137.5 vs.
223.1 ± 3.0 μm2, p = 0.009) and the MR sinus patients
(436.5 ± 65.0 vs. 223.1 ± 3.0 μm2, p = 0.011) significantly
exceeded the average cell surface area of myocyte in the left
atrial tissue of the normal control subjects (Fig. 1). The
average cell surface areas of myocytes in the left atrial tis-
sue did not significantly differ between the MR AF group
and the MR sinus group (p = 0.187). The average nuclearsize of myocytes in the left atrial tissues of the MR AF pa-
tients (50.4 ± 5.8 vs. 21.4 ± 1.7 μm2, p = 0.009) and the MR
sinus patients (44.5 ± 4.3 vs. 21.4 ± 1.7 μm2, p = 0.011)
significantly exceeded the average nuclear size of myo-
cytes in the left atrial tissue of the normal control subjects
(Fig. 1). The average nuclear size of myocytes in the left
atrial tissue did not significantly differ between the MR
AF group and the MR sinus group (p = 0.598).
The most prominent change in cellular substructure
observed in a significant number of atrial myocytes from
patients with MR was the depletion of contractile mate-
rials without cell volume loss (myolysis) (Figs. 1 and 2).
Loss of contractile materials in many cells was mainly
limited to the vicinity of the nucleus, and in some cases,
it involved most of the cytoplasm, leaving only a few sar-
comeres at the periphery of the cell. The myolytic area
per myocyte in the left atrial tissues of the MR AF pa-
tients (203.9 ± 89.5 vs. 3.1 ± 1.2 μm2, p = 0.021) signifi-
cantly exceeded the myolytic area per myocyte in the left
atrial tissue of the normal control subjects (Fig. 1). The
Fig. 1 The average cell surface area, average nuclear size, and myolytic area per myocyte in the left atrial tissues of mitral regurgitation patients with
sinus rhythm, mitral regurgitation patients with atrial fibrillation (AF) and normal control. * p < 0.05.
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MR sinus patients (73.4 ± 26.8 vs. 3.1 ± 1.2 μm2, p = 0.063)
exceeded the myolytic area per myocyte in the left atrial
tissue of the normal control subjects (Fig. 1). The inci-
dence of atrial myocytes displayed moderate-to-severe
myolysis in the left atrial tissues of the MR AF patients
significantly exceeded that in the left atrial tissue of the
normal control subjects (38.6 ± 11.3 vs. 1.7 ± 1.7 %,
p = 0.043) (Fig. 3). The incidence of atrial myocytes dis-
played moderate-to-severe myolysis in the left atrial tis-
sues of the MR sinus patients exceeded that in the left
atrial tissue of the normal control subjects (37.1 ± 12.0 vs.
1.7 ± 1.7 %, p = 0.087) (Fig. 3).Fig. 2 Immunofluorescence images of the normal human adult left atrial tissu
with sinus rhythm (middle panel, B), and left atrial tissue of mitral regurgitation
with perinuclear sarcomere depletion (myolysis) (arrows) were found in mitral
AF. Whereas in normal control atrial sample, myofibrils were organized in a w
Myocyte identification was performed with phalloidin-FITC F-actin (green coloExpression of ROCKs and cleaved caspase-3 in atrial
myocytes of mitral regurgitation
The expression of ROCK2 in left atrial myocytes of the MR
AF patients (5392063.5 ± 754041.5 vs. 1645229.6 ± 33370.6,
p = 0.009) and the MR sinus patients (3404491.7 ± 651556.7
vs. 1645229.6 ± 33370.6, p = 0.043) were significantly
higher than the expression of ROCK2 of the normal con-
trol subjects (Fig. 4). Of note, the expression of ROCK2 in
the myolytic left atrial myocytes of the MR AF patients
(5783291.5 ± 745382.4 vs. 1635719.8 ± 465425.9, p = 0.009)
and the MR sinus patients (3981370.8 ± 457612.4 vs.
1635719.8 ± 465425.9, p = 0.011) were significantly higher
than the expression of ROCK2 in the myolytic left atriale sample (left panel, A), left atrial tissue of mitral regurgitation patients
patients with atrial fibrillation (AF) (right panel, C). Numerous myocytes
regurgitation patients with sinus and mitral regurgitation patients with
ell-aligned and striated network (no myolysis in the myocytes in panel A).
r). Bar = 20 μm.
Fig. 3 The percentage of atrial myocytes displayed no myolysis, mild myolysis, and moderate-to-severe myolysis in the left atrial tissues of mitral
regurgitation patients with sinus rhythm, mitral regurgitation patients with atrial fibrillation (AF) and normal control. * p < 0.05.
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However, the expression of ROCK2 in the non-myolytic
left atrial myocytes of the MR AF patients (3608241.7 ±
720425.7 vs. 2044794.5 ± 422720.6, p = 0.386) and the MR
sinus patients (2208837.8 ± 624203.5 vs. 2044794.5 ±
422720.6, p = 0.612) did not significantly differ from the
expression of ROCK2 in the non-myolytic left atrial myo-
cytes of the normal control subjects (Fig. 4). Interestingly,
the expression of ROCK2 in the myolytic left atrial myo-
cytes was significantly higher in the MR AF patients than
the MR sinus patients (p < 0.05) (Fig. 4). Of note, correl-
ation analysis demonstrated that there was a significant
direct relationship between the expression of ROCK2 in
the myolytic left atrial myocytes and left atrial diameter in
the MR patients (p = 0.037; r = 0.446) (Fig. 6). The expres-
sion of ROCK2 protein (normalized to GAPDH) by im-
munoblotting in left atrial tissues of the MR AF patients
(n = 6) was significantly higher than the expression of
ROCK2 of the normal control subjects (n = 3) (2.32 ± 0.18
vs. 0.53 ± 0.16, p = 0.020) (Fig. 7a). The expression of
ROCK2 protein by immunoblotting in left atrial tissues of
the MR sinus patients (n = 4) was higher than the expres-
sion of ROCK2 of the normal control subjects (n = 3)
(0.85 ± 0.10 vs. 0.53 ± 0.16, p = 0.157) (Fig. 7a). The ex-
pression of ROCK2 protein by immunoblotting in left
atrial tissues of the MR AF patients was significantly
higher than the expression of ROCK2 of the MR sinus pa-
tients (p = 0.011).
The expression of ROCK1 in left atrial myocytes of the
MR AF patients was significantly higher than the expression
of ROCK1 of the normal control subjects (2033899.5 ±
172865.3 vs. 1132555.5 ± 42027.4, p= 0.016) (Figs. 4 and 8).Of note, the expression of ROCK1 in the myolytic left atrial
myocytes of the MR AF patients was significantly higher
than the expression of ROCK1 in the myolytic left atrial
myocytes of the normal control subjects (2173527.6 ±
159745.3 vs. 978383.3 ± 116680.7, p = 0.010). However, the
expression of ROCK1 in the non-myolytic left atrial myo-
cytes of the MR AF patients did not significantly differ from
the expression of ROCK1 in the non-myolytic left atrial
myocytes of the normal control subjects (1303403.2 ±
257033.5 vs. 1248082.3 ± 50698.5, p = 0.815). Interestingly,
the expression of ROCK1 in left atrial myocytes of the MR
AF patients was significantly higher than that of the MR
sinus patients (2033899.5 ± 172865.3 vs. 1514957.0 ±
231591.3, p = 0.041) (Figs. 4 and 8). The expression of
ROCK1 in the myolytic left atrial myocytes of the MR AF
patients was higher than that of the MR sinus patients
(2173527.6 ± 159745.3 vs. 1804745.3 ± 302136.4, p = 0.091).
The expression of ROCK1 in left atrial myocytes of the MR
sinus patients was higher than the expression of ROCK1 of
the normal control subjects (1514957.0 ± 231591.3 vs.
1132555.5 ± 42027.4, p = 0.398). The expression of ROCK1
in the myolytic left atrial myocytes of the MR sinus patients
was higher than the expression of ROCK1 in the myolytic
left atrial myocytes of the normal control subjects
(1804745.3 ± 302136.4 vs. 978383.3 ± 116680.7, p = 0.091)
(Figs. 4 and 8). Of note, correlation analysis demonstrated
that there was a direct relationship between the expression
of ROCK1 in the myolytic left atrial myocytes and left atrial
diameter in the MR patients (p = 0.057; r = 0.422). The ex-
pression of ROCK1 protein (normalized to GAPDH) by
immunoblotting in left atrial tissues of the MR AF pa-
tients (n = 6) was significantly higher than the expression
Fig. 4 The expression of ROCK2, ROCK1 and cleaved caspase-3 in the myolytic and non-myolytic left atrial myocytes of mitral regurgitation patients
with sinus rhythm, mitral regurgitation patients with atrial fibrillation (AF) and normal control. * p < 0.05.
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0.078 vs. 0.004 ± 0.003, p = 0.039) (Fig. 7b). The expression
of ROCK1 protein by immunoblotting in left atrial tissues
of the MR sinus patients (n = 4) was significantly higher
than the expression of ROCK1 of the normal control sub-
jects (n = 3) (0.090 ± 0.036 vs. 0.004 ± 0.003, p = 0.034)
(Fig. 7b). The expression of ROCK1 protein by immuno-
blotting in left atrial tissues of the MR AF patients was
higher than the expression of ROCK1 of the MR sinus pa-
tients but the difference did not reach statistical signifi-
cance (p = not significant).
The ROCK activity is expressed as a relative blot density
ratio (pMBS sample density/tMBS sample density) [27].
The ratio of pMBS/tMBS of left atrial tissues was signifi-
cantly higher in the MR AF group compared with the nor-
mal control group (0.30 ± 0.11 vs. 0.02 ± 0.01, p < 0.04)
(Fig. 9). Similarly, the ratio of pMBS/tMBS of left atrial tis-
sues was significantly higher in the MR sinus group com-
pared with the normal control group (0.10 ± 0.03 vs. 0.02 ±
0.01, p < 0.04) (Fig. 9).The expression of cleaved (activated form) caspase-3 in
left atrial myocytes of the MR AF patients (4625762.9 ±
975783.2 vs. 1530603.3 ± 189545.3, p = 0.009) and the MR
sinus patients (3499251.8 ± 594548.3 vs. 1530603.3 ±
189545.3, p = 0.018) were significantly higher than the ex-
pression of cleaved caspase-3 of the normal control sub-
jects (Fig. 4). Of note, the expression of cleaved caspase-3
in the myolytic left atrial myocytes of the MR AF patients
(4891266.4 ± 952777.4 vs. 1932986.9 ± 280229.3, p = 0.021)
and the MR sinus patients (3785119.0 ± 540198.5 vs.
1932986.9 ± 280229.3, p = 0.018) were significantly higher
than the expression of cleaved caspase-3 in the myolytic
left atrial myocytes of the normal control subjects (Figs. 4
and 5). However, the expression of cleaved caspase-3 in
the non-myolytic left atrial myocytes of the MR AF pa-
tients (2691764.1 ± 593821.1 vs. 1621900.3 ± 39281.4, p =
0.470) and the MR sinus patients (1970992.5 ± 524326.6
vs. 1621900.3 ± 39281.4, p = 0.236) did not significantly
differ from the expression of cleaved caspase-3 in the non-
myolytic left atrial myocytes of the normal control
Fig. 5 Confocal images of the expression of ROCK2 (green color) and cleaved (activated) caspase-3 (red color) in the normal human adult left atrial
tissue sample (upper panels), left atrial tissue of mitral regurgitation patients with sinus rhythm (middle panels), and left atrial tissue of mitral regurgitation
patients with atrial fibrillation (AF) (lower panels). Merge pictures revealed co-localization (insets, arrowhead, yellow spots) of expression of ROCK2
and cleaved caspase-3 in the left atrial tissue of mitral regurgitation patients with sinus rhythm (middle panel), and mitral regurgitation patients
with AF (lower panel). Myolysis (arrow) was mainly found in mitral regurgitation patients with sinus rhythm and mitral regurgitation patients with
AF. Bar = 20 μm.
Fig. 6 Correlation between the average integrated intensity of ROCK2 in the myolytic left atrial myocytes and the left atrial (LA) diameter in the
mitral regurgitation patients. Each point represented one patient with mitral regurgitation.
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Fig. 7 The expression levels of ROCK2 (left panel, A), ROCK1 (middle panel, B) and cleaved caspase-3 (right panel, C) in the left atrial tissue extracts were
determined by Western blotting in the normal human adult left atrial tissue samples (n = 3), mitral regurgitation patients with sinus rhythm (n = 4: small
number due to lack of enough tissue samples), and mitral regurgitation patients with atrial fibrillation (AF) (n = 6).
Fig. 8 Confocal images of the expression of ROCK1 (green color) and cleaved (activated) caspase-3 (red color) in the normal human adult left atrial
tissue sample (upper panels), left atrial tissue of mitral regurgitation patients with sinus rhythm (middle panels), and left atrial tissue of mitral regurgitation
patients with atrial fibrillation (AF) (lower panels). Merge pictures revealed co-localization (insets, arrowhead, yellow spots) of expression of ROCK1
and cleaved caspase-3 in the left atrial tissue of mitral regurgitation patients with sinus rhythm (middle panel), and mitral regurgitation patients
with AF (lower panel). Myolysis (arrow) was mainly found in mitral regurgitation patients with sinus rhythm and mitral regurgitation patients with
AF. Bar = 20 μm.
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Fig. 9 The expression levels of the phosphorylation level of myosin-binding
subunit of myosin light chain phosphatase (pMBS), and of the total
MBS (tMBS) (normalized to GAPDH) in the left atrial tissue extracts were
determined by Western blotting in the normal human adult left atrial
tissue samples (left panel; n = 3), mitral regurgitation patients with sinus
rhythm (middle panel; n = 4: small number due to lack of enough tissue
samples), and mitral regurgitation patients with atrial fibrillation (AF)
(right panel; n = 6). The ROCK activity is expressed as a relative blot
density ratio (pMBS sample density/tMBS sample density).
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tic left atrial myocytes of the MR AF patients did not differ
from the expression of cleaved caspase-3 in the myolytic
left atrial myocytes of the MR sinus patients (p = 0.644).
The expression of cleaved caspase-3 protein (normalized
to GAPDH) by immunoblotting in left atrial tissues of the
MR AF patients (n = 6) was significantly higher than the
expression of cleaved caspase-3 of the normal control sub-
jects (n = 3) (0.20 ± 0.04 vs. 0.04 ± 0.02, p = 0.039) (Fig. 7c).
The expression of cleaved caspase-3 protein by immuno-
blotting in left atrial tissues of the MR sinus patients
(n = 4) was higher than the expression of cleaved caspase-
3 of the normal control subjects (n = 3) (0.09 ± 0.02 vs.
0.04 ± 0.02, p = 0.157). The expression of cleaved caspase-
3 protein by immunoblotting in left atrial tissues of the
MR AF patients was higher than the expression of cleaved
caspase-3 of the MR sinus patients (p = 0.055).
Immunofluorescence study revealed a significant co-
localization and juxtaposition of the expression of ROCK2and the expression of cleaved caspase-3 in the left atrial
myocytes both in the MR AF group (Pearson’s coefficient =
0.74 ± 0.03) and the MR sinus group (Pearson’s coefficient =
0.73 ± 0.02) (Fig. 5), indicating the existence of potential
interaction between ROCK2 and cleaved caspase-3 and
confirmation of caspase-dependent activation of ROCK2 in
the left atrial myocytes of MR patients, and this interaction
might be involved in the pathogenesis of left atrial myolysis
in MR patients. Similarly, immunofluorescence study re-
vealed a significant co-localization and juxtaposition of the
expression of ROCK1 and the expression of cleaved
caspase-3 in the left atrial myocytes both in the MR AF
group (Pearson’s coefficient = 0.65 ± 0.03) and the MR
sinus group (Pearson’s coefficient = 0.65 ± 0.03) (Fig. 8).
Discussion
This study of symptomatic severe MR indicated that the
expression levels of activated caspase 3 and ROCK2, and
ROCK activity were significantly enhanced in the left
atrial myocytes of MR patients. Moreover, the enhanced
expression of activated caspase 3 and ROCK2 was sig-
nificantly associated with the presence of myolysis. To
the best of our knowledge, this is the first study to dem-
onstrate evidence of the activation of ROCK2 in the
myolytic left atrial myocytes of patients with MR.
The most prominent histologic findings from surgical
atrial specimens of patients with mitral valve disease are
myocyte hypertrophy and myolysis, even in the absence of
AF [7, 11, 28, 29]. Myolysis is a degenerative changes ac-
companied with loss of myofibrils, presence of glycogen
granules, accumulation of sarcoplasmic reticulum-like
material, and aggregates of mitochondria. The underlying
mechanisms of myolysis remain unclear. This study
showed that myolysis occurred in 70.6 ± 8.1 % of myocytes
in the MR AF group, and in 62.7 ± 10.7 % of myocytes in
the MR sinus group.
ROCKs play an important role in many cellular func-
tions, including proliferation, migration, adhesion, con-
traction, gene expression, and apoptosis [18–22].
Additionally, activity of ROCKs has been reported to be
related to the development of many cardiovascular dis-
eases [12–17]. Previous studies showed that upregulation
of the RhoA/ROCK pathway contributes to a cellular con-
text that switches-on myosin-mediated contraction, and
consequently caspase-3 activation, which is an important
mechanism for triggering apoptotic induction [18, 26, 30].
Moreover, ROCKs are important in the regulation of cyto-
skeleton integrity of cells and actomyosin contractility. In
this study, the expression levels of activated caspase 3 and
ROCK2, and ROCK activity were significantly enhanced
and the expression level of ROCK1 was substantially en-
hanced in the myolytic left atrial myocytes of MR patients
(Figs. 4, 5, 8 and 9). Furthermore, there was a significant
co-localization and juxtaposition of ROCK2 and ROCK1
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However, the expression levels of activated caspase 3,
ROCK1 and ROCK2 were not enhanced in the non-
myolytic left atrial myocytes. Therefore, this study showed
that the interaction between activated caspase 3 and
ROCK activity might play a role in the development of
myolysis. Interestingly, this study showed that the expres-
sion of ROCK2 in the myolytic left atrial myocytes was
significantly higher in the MR AF patients than the MR
sinus patients (p < 0.05). Further studies should be con-
ducted to elucidate the mechanisms of this observation.
Clinical implications
The study suggested that the interaction between acti-
vated caspase 3 and ROCK activity was associated with
the development of myolysis in the left atrial myocytes
of MR patients. Myolysis is an important mechanism of
atrial contractile dysfunction and atrial enlargement,
which is an important prognostic factor in patients with
MR. The results of this study indicated that inhibition of
ROCK2 may be potential candidate target to prevent left
atrial contractile dysfunction and left atrial enlargement
in patients with MR.
Study limitations
The limitations of this study should be addressed. Firstly,
the sample size of this study was relatively small. How-
ever, the results were significant. Secondly, the regula-
tion between activated caspase 3 and ROCK activity was
not investigated in this study and our results provide av-
enues of future study.
Conclusions
The expression levels of activated caspase 3 and ROCK2,
and ROCK activity were significantly enhanced in the
left atrial myocytes of MR patients. Significant co-
localization and juxtaposition of ROCK2 and cleaved
caspase-3 was found in the myolytic left atrial myocytes
of MR patients. Moreover, the enhanced expression of
activated caspase 3 and ROCK2 was significantly associ-
ated with the presence of myolysis. The enhanced ex-
pression of ROCK2 might be involved in the myolysis of
the left atrial myocytes of MR patients.
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